

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Martin Nicklasson</i>
b)	Position	<i>Chair of the Board</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 200,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 200,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Anders Tuv</i>
b)	Position	<i>Board Member</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 45,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 45,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Anne Whitaker</i>
b)	Position	<i>Board Member</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 45,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 45,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Elaine Sullivan</i>
b)	Position	<i>Board Member</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 45,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 45,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Bernd R. Seizinger</i>
b)	Position	<i>Board Member</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 45,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 45,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Birgitte Volck</i>
b)	Position	<i>Board Member</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of board remuneration</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume</b> 45,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 0</p> <p><b>Volume</b> 45,000</p> <p><b>Total amount</b> NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Michael Engsig</i>
b)	Position	<i>Chief Executive Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 334,927</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 334,927 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Harald Gurvin</i>
b)	Position	<i>Chief Financial Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 140,214</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 140,214 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Agnete B. Fredriksen</i>
b)	Position	<i>Chief Innovation &amp; Strategy Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 128,997</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 128,997 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Mikkel W. Pedersen</i>
b)	Position	<i>Chief Scientific Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 123,348</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 123,348 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Mette Husbyn</i>
b)	Position	<i>Chief Technology Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 55,777</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 55,777 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Katrine Husum</i>
b)	Position	<i>Senior Director, Head of Project and Alliance Management</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics AS</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Options with shares in Nykode Therapeutics AS (ISIN: NO0010714785) as underlying</i>
b)	Nature of the transaction	<i>Grant of share options as part of remuneration package</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 0</p> <p><b>Volume(s)</b> 56,383</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> <b>Volume</b> <b>Total amount</b></p> <p>NOK 0 56,383 NOK 0</p>
e)	Date of the transaction	<i>16.05.2022</i>
f)	Place of the transaction	<i>Outside of trading venue</i>